H Liu, J Li, E Ziegemeier, S Adams, E McDade, D B Clifford, Y Cao, G Wang, Y Li, S L Mills, A M Santacruz, S Belyew, J D Grill, B J Snider, C J Mummery, G Surti, D Hannequin, D Wallon, S B Berman, I Z Jimenez-Velazquez, E D Roberson, C H van Dyck, L S Honig, R Sanchez-Valle, W S Brooks, S Gauthier, D Galasko, C L Masters, J Brosch, G-Y R Hsiung, S Jayadev, M Formaglio, M Masellis, R Clarnette, J Pariente, B Dubois, F Pasquier, R J Bateman, J J Llibre-Guerra
BACKGROUND: Clinical trial satisfaction is increasingly important for future trial designs and is associated with treatment adherence and willingness to enroll in future research studies or to recommend trial participation. In this post-trial survey, we examined participant satisfaction and attitudes toward future clinical trials in the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU). METHODS: We developed an anonymous, participant satisfaction survey tailored to participants enrolled in the DIAN-TU-001 double-blind clinical trial of solanezumab or gantenerumab and requested that all study sites share the survey with their trial participants...
2024: Journal of Prevention of Alzheimer's Disease